FOR PATIENTS
SQZ® Cell Therapies Seek to Put Your
Immune System to Work Against Disease

About Our Approach

We use a patient’s own cells to manufacture a personalized therapy. After blood collection, we isolate target cell types, use our SQZ® technology to engineer their functions and administer them back to the patient. This manufacturing process typically takes less than 24hrs and a patient can receive their first dose about a week after blood collection. Once administered, SQZ® engineered cells are designed to home to specialized immune structures, such as the lymph nodes and spleen, and direct the patient’s immune system to target disease.

Our clinical program is in oncology for the treatment of HPV16 positive cancers.

The Patient Experience


No preconditioning


No lengthy hospital stays


Time to treatment: ~1wk


Administration is a simple syringe push

Patients and their physicians can expect rapid answers to questions about our clinical trial. Your time is important, and we will endeavor to respond with urgency.
patientadvocacy@sqzbiotech.com

Current Active Enrollment · Oncology

SQZ Biotech is actively enrolling in the following trial for patients with HPV16+ cancers with multiple sites in the United States.

Enrolling HPV+ Cancers

  • Anal
  • Cervical
  • Head and Neck
  • Penile
  • Rectal
  • Vaginal
  • Vulvar

Eligibility

  • Male or Female 18 years of age or older
  • Histologically confirmed incurable or metastatic solid tumors that are HPV16+
  • Cancer progression after at least one available standard therapy for incurable disease, or patient is intolerant to or refuses standard therapy(ies) or has a tumor for which no standard therapy(ies) exist
COMMANDER-001 · PHASE 1/2 CLINICAL TRIAL
Enhanced APC (eAPC) therapeutic candidate derived from patient’s own white blood cells
  • Designed to leverage the advantages and functionalities of five different mRNAs squeezed into white blood cells
  • Administered as monotherapy or in combination with checkpoint inhibitor pembrolizumab
  • In preclinical studies, SQZ® eAPCs have been shown to generate robust CD8 T cell responses against multiple antigens, through simultaneous expression of antigens, CD86, membrane bound IL-2, and membrane bound IL-12

Learn about the science behind COMMANDER-001
Trial and enrollment details
Download Trial Information for Patients

Expanded Access Policy

In expanded access programs, patients with serious diseases or life-threatening conditions who have exhausted all available options and do not meet the eligibility criteria to participate in a clinical trial may be able to access investigational therapies. At this time in our clinical development path, however, we do not offer expanded access as we believe that enrollment in our clinical trial is the best way for us to develop safe and effective treatments that would ultimately benefit a larger number of patients.

We encourage all patients and physicians who are interested in accessing our investigational therapy to contact us for information. You can also visit trial and enrollment details and see additional details on clinicaltrials.gov

COMMANDER-001 ENROLLING SITES

  • HonorHealth, Scottsdale, AZ
  • University of Colorado, Aurora, CO
  • Tenessee Oncology, Nashville, TN
  • University of Cincinnati, Cincinnati, OH
  • Massachusetts General Hospital, Boston, MA
  • More sites expected to open soon!

Patient Advocacy

We are committed to advancing the clinical development of cell therapies that are safe, effective and accessible to patients worldwide. We are actively engaged with leading advocacy organizations working to support patients and their families living with cancer. For additional information on HPV+ cancers, the following organizations can provide educational and other resources.

We are not responsible for content provided by these organizations.